Advertisement

Blood Biomarkers for Acute CNS Insults: Traumatic Brain Injury and Stroke

  • Olena Glushakova
  • Stefania Mondello
  • Ronald L. HayesEmail author
Chapter
Part of the Springer Series in Translational Stroke Research book series (SSTSR, volume 5)

Abstract

Proteins that are expressed in the central nervous system (CNS) are often detectable in peripheral blood and the search for biomarkers or biological signals for specific diseases and injury processes, including traumatic brain injury (TBI), has rapidly expanded. Currently no accurate biochemical assessment exists for objectively identifying the extent of damage following TBI. The ability to accurately determine the extent of initial severity of primary brain damage after TBI in the acute care setting is critical for the establishment of accurate neurologic prognosis and the guidance of appropriate therapeutic strategies (Nat Rev Neurol 9, 192–200, 2013; Neurotherapeutics 7, 100–114, 2010). This chapter will review the most current literature concerning the novel utility of blood biomarker assessment for the diagnosis and prognosis of patients with TBI.

Keywords

Traumatic Brain Injury Glial Fibrillary Acidic Protein Severe Traumatic Brain Injury Traumatic Brain Injury Patient Mild Traumatic Brain Injury 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Langlois JA, Rutland-Brown W, Wald MM (2006) The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil 21:375–378PubMedGoogle Scholar
  2. 2.
    Okie S (2005) Traumatic brain injury in the war zone. N Engl J Med 352:2043–2047PubMedGoogle Scholar
  3. 3.
    Sapsford W (2003) Penetrating brain injury in military conflict: does it merit more research? J R Army Med Corps 149:5–14PubMedGoogle Scholar
  4. 4.
    Faul M, Wald MM, Sullivent EE, Sasser SM, Kapil V, Lerner EB, Hunt RC (2012) Large cost savings realized from the 2006 Field Triage Guideline: reduction in overtriage in U.S. trauma centers. Prehosp Emerg Care 16:222–229PubMedGoogle Scholar
  5. 5.
    Mccrory P, Meeuwisse W, Johnston K, Dvorak J, Aubry M, Molloy M, Cantu R (2009) Consensus statement on concussion in sport–the 3rd international conference on concussion in sport held in Zurich, November 2008. J Sci Med Sport 12:340–351PubMedGoogle Scholar
  6. 6.
    Vollmer DG, Dacey RG Jr (1991) The management of mild and moderate head injuries. Neurosurg Clin N Am 2:437–455PubMedGoogle Scholar
  7. 7.
    Yealy DM, Hogan DE (1991) Imaging after head trauma. Who needs what? Emerg Med Clin North Am 9:707–717PubMedGoogle Scholar
  8. 8.
    Giza CC, Hovda DA (2001) The neurometabolic cascade of concussion. J Athl Train 36:228–235PubMedGoogle Scholar
  9. 9.
    Vagnozzi R, Signoretti S, Cristofori L, Alessandrini F, Floris R, Isgro E, Ria A, Marziale S, Zoccatelli G, Tavazzi B, Del Bolgia F, Sorge R, Broglio SP, Mcintosh TK, Lazzarino G (2010) Assessment of metabolic brain damage and recovery following mild traumatic brain injury: a multicentre, proton magnetic resonance spectroscopic study in concussed patients. Brain 133:3232–3242PubMedGoogle Scholar
  10. 10.
    Vagnozzi R, Signoretti S, Tavazzi B, Floris R, Ludovici A, Marziali S, Tarascio G, Amorini AM, Di Pietro V, Delfini R, Lazzarino G (2008) Temporal window of metabolic brain vulnerability to concussion: a pilot 1H-magnetic resonance spectroscopic study in concussed athletes–part III. Neurosurgery 62:1286–1295; discussion 1295–1296PubMedGoogle Scholar
  11. 11.
    Guskiewicz KM, Marshall SW, Bailes J, Mccrea M, Cantu RC, Randolph C, Jordan BD (2005) Association between recurrent concussion and late-life cognitive impairment in retired professional football players. Neurosurgery 57:719–726; discussion 719–726PubMedGoogle Scholar
  12. 12.
    Guskiewicz KM, Marshall SW, Bailes J, Mccrea M, Harding HP Jr, Matthews A, Mihalik JR, Cantu RC (2007) Recurrent concussion and risk of depression in retired professional football players. Med Sci Sports Exerc 39:903–909PubMedGoogle Scholar
  13. 13.
    Lovell MR, Pardini JE, Welling J, Collins MW, Bakal J, Lazar N, Roush R, Eddy WF, Becker JT (2007) Functional brain abnormalities are related to clinical recovery and time to return-to-play in athletes. Neurosurgery 61:352–359; discussion 359–360PubMedGoogle Scholar
  14. 14.
    Mccrea M, Guskiewicz K, Randolph C, Barr WB, Hammeke TA, Marshall SW, Powell MR, Woo Ahn K, Wang Y, Kelly JP (2013) Incidence, clinical course, and predictors of prolonged recovery time following sport-related concussion in high school and college athletes. J Int Neuropsychol Soc 19:22–33PubMedGoogle Scholar
  15. 15.
    Mccrea M, Guskiewicz KM, Marshall SW, Barr W, Randolph C, Cantu RC, Onate JA, Yang J, Kelly JP (2003) Acute effects and recovery time following concussion in collegiate football players: the NCAA Concussion Study. JAMA 290:2556–2563PubMedGoogle Scholar
  16. 16.
    Mccrea M, Kelly JP, Randolph C, Cisler R, Berger L (2002) Immediate neurocognitive effects of concussion. Neurosurgery 50:1032–1040; discussion 1040–1042PubMedGoogle Scholar
  17. 17.
    Petraglia AL, Maroon JC, Bailes JE (2012) From the field of play to the field of combat: a review of the pharmacological management of concussion. Neurosurgery 70:1520–1533; discussion 1533PubMedGoogle Scholar
  18. 18.
    Jordan BD (2013) The clinical spectrum of sport-related traumatic brain injury. Nat Rev Neurol 9:222–230PubMedGoogle Scholar
  19. 19.
    Dekosky ST, Blennow K, Ikonomovic MD, Gandy S (2013) Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol 9:192–200PubMedGoogle Scholar
  20. 20.
    Goldstein LE, Fisher AM, Tagge CA, Zhang XL, Velisek L, Sullivan JA, Upreti C, Kracht JM, Ericsson M, Wojnarowicz MW, Goletiani CJ, Maglakelidze GM, Casey N, Moncaster JA, Minaeva O, Moir RD, Nowinski CJ, Stern RA, Cantu RC, Geiling J, Blusztajn JK, Wolozin BL, Ikezu T, Stein TD, Budson AE, Kowall NW, Chargin D, Sharon A, Saman S, Hall GF, Moss WC, Cleveland RO, Tanzi RE, Stanton PK, Mckee AC (2012) Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med 4:134ra60PubMedGoogle Scholar
  21. 21.
    Mckee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, Santini VE, Lee HS, Kubilus CA, Stern RA (2009) Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 68:709–735PubMedGoogle Scholar
  22. 22.
    Mckee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall NW, Perl DP, Hedley-Whyte ET, Price B, Sullivan C, Morin P, Lee HS, Kubilus CA, Daneshvar DH, Wulff M, Budson AE (2010) TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 69:918–929PubMedGoogle Scholar
  23. 23.
    Mckee AC, Stein TD, Nowinski CJ, Stern RA, Daneshvar DH, Alvarez VE, Lee HS, Hall G, Wojtowicz SM, Baugh CM, Riley DO, Kubilus CA, Cormier KA, Jacobs MA, Martin BR, Abraham CR, Ikezu T, Reichard RR, Wolozin BL, Budson AE, Goldstein LE, Kowall NW, Cantu RC (2013) The spectrum of disease in chronic traumatic encephalopathy. Brain 136:43–64PubMedGoogle Scholar
  24. 24.
    Xiong H, Liang WL, Wu XR (2000) Pathophysiological alterations in cultured astrocytes exposed to hypoxia/reoxygenation. Sheng Li Ke Xue Jin Zhan 31:217–221PubMedGoogle Scholar
  25. 25.
    Mondello S, Muller U, Jeromin A, Streeter J, Hayes RL, Wang KK (2011) Blood-based diagnostics of traumatic brain injuries. Expert Rev Mol Diagn 11:65–78PubMedGoogle Scholar
  26. 26.
    Isobe T, Ishioka N, Okuyama T (1981) Structural relation of two S-100 proteins in bovine brain; subunit composition of S-100a protein. Eur J Biochem 115:469–474PubMedGoogle Scholar
  27. 27.
    Graham MR, Myers T, Evans P, Davies B, Cooper SM, Bhattacharya K, Grace FM, Baker JS (2011) Direct hits to the head during amateur boxing is associated with a rise in serum biomarkers for brain injury. Int J Immunopathol Pharmacol 24:119–125PubMedGoogle Scholar
  28. 28.
    Sawada M, Kondo N, Suzumura A, Marunouchi T (1989) Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 491:394–397PubMedGoogle Scholar
  29. 29.
    Stalnacke BM, Ohlsson A, Tegner Y, Sojka P (2006) Serum concentrations of two biochemical markers of brain tissue damage S-100B and neurone specific enolase are increased in elite female soccer players after a competitive game. Br J Sports Med 40:313–316PubMedGoogle Scholar
  30. 30.
    Metting Z, Wilczak N, Rodiger LA, Schaaf JM, van der Naalt J (2012) GFAP and S100B in the acute phase of mild traumatic brain injury. Neurology 78:1428–1433PubMedGoogle Scholar
  31. 31.
    Muller K, Townend W, Biasca N, Unden J, Waterloo K, Romner B, Ingebrigtsen T (2007) S100B serum level predicts computed tomography findings after minor head injury. J Trauma 62:1452–1456PubMedGoogle Scholar
  32. 32.
    Topolovec-Vranic J, Pollmann-Mudryj MA, Ouchterlony D, Klein D, Spence J, Romaschin A, Rhind S, Tien HC, Baker AJ (2011) The value of serum biomarkers in prediction models of outcome after mild traumatic brain injury. J Trauma 71:S478–S486PubMedGoogle Scholar
  33. 33.
    Raabe A, Menon DK, Gupta S, Czosnyka M, Pickard JD (1998) Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study. J Neurol Neurosurg Psychiatry 65:930–932PubMedGoogle Scholar
  34. 34.
    Romner B, Ingebrigtsen T, Kongstad P, Borgesen SE (2000) Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. J Neurotrauma 17:641–647PubMedGoogle Scholar
  35. 35.
    Woertgen C, Rothoerl RD, Metz C, Brawanski A (1999) Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. J Trauma 47:1126–1130PubMedGoogle Scholar
  36. 36.
    Herrmann M, Curio N, Jost S, Wunderlich MT, Synowitz H, Wallesch CW (1999) Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury. Restor Neurol Neurosci 14:109–114Google Scholar
  37. 37.
    Kovesdi E, Luckl J, Bukovics P, Farkas O, Pal J, Czeiter E, Szellar D, Doczi T, Komoly S, Buki A (2010) Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. Acta Neurochir (Wien) 152:1–17Google Scholar
  38. 38.
    Mckeating EG, Andrews PJ, Mascia L (1998) Relationship of neuron specific enolase and protein S-100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. Acta Neurochir Suppl 71:117–119PubMedGoogle Scholar
  39. 39.
    Mondello S, Papa L, Buki A, Bullock MR, Czeiter E, Tortella FC, Wang KK, Hayes RL (2011) Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care 15:R156PubMedGoogle Scholar
  40. 40.
    Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H (2004) GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 21:1553–1561PubMedGoogle Scholar
  41. 41.
    Raabe A, Grolms C, Keller M, Dohnert J, Sorge O, Seifert V (1998) Correlation of computed tomography findings and serum brain damage markers following severe head injury. Acta Neurochir (Wien) 140:787–791; discussion 791–792Google Scholar
  42. 42.
    Raabe A, Grolms C, Sorge O, Zimmermann M, Seifert V (1999) Serum S-100B protein in severe head injury. Neurosurgery 45:477–483PubMedGoogle Scholar
  43. 43.
    Rothoerl RD, Woertgen C, Holzschuh M, Metz C, Brawanski A (1998) S-100 serum levels after minor and major head injury. J Trauma 45:765–767PubMedGoogle Scholar
  44. 44.
    Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemela O, Hillbom M (2004) Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma 56:1229–1234; discussion 1234PubMedGoogle Scholar
  45. 45.
    Unden J, Astrand R, Waterloo K, Ingebrigtsen T, Bellner J, Reinstrup P, Andsberg G, Romner B (2007) Clinical significance of serum S100B levels in neurointensive care. Neurocrit Care 6:94–99PubMedGoogle Scholar
  46. 46.
    Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T, Edwards M, Rosmalen CF, Vissers JL (2010) GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 75:1786–1793PubMedGoogle Scholar
  47. 47.
    Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, van Geel W, de Reus H, Biert J, Verbeek MM (2004) Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 62:1303–1310PubMedGoogle Scholar
  48. 48.
    Woertgen C, Rothoerl RD, Holzschuh M, Metz C, Brawanski A (1997) Comparison of serial S-100 and NSE serum measurements after severe head injury. Acta Neurochir (Wien) 139:1161–1164; discussion 1165Google Scholar
  49. 49.
    Egea-Guerrero JJ, Revuelto-Rey J, Murillo-Cabezas F, Munoz-Sanchez MA, Vilches-Arenas A, Sanchez-Linares P, Dominguez-Roldan JM, Leon-Carrion J (2012) Accuracy of the S100beta protein as a marker of brain damage in traumatic brain injury. Brain Inj 26:76–82PubMedGoogle Scholar
  50. 50.
    Defazio MV, Rammo RA, Robles JR, Bramlett HM, Dietrich WD, Bullock MR (2013) The potential utility of blood-derived biochemical markers as indicators of early clinical trends after severe traumatic brain injury. World NeurosurgGoogle Scholar
  51. 51.
    Babcock L, Byczkowski T, Mookerjee S, Bazarian JJ (2012) Ability of S100B to predict severity and cranial CT results in children with TBI. Brain Inj 26:1372–1380PubMedGoogle Scholar
  52. 52.
    Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM (2005) Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg 103:61–68PubMedGoogle Scholar
  53. 53.
    Goyal A, Carter M, Niyonkuru C, Fabio A, Amin K, Berger RP, Wagner AMD (2013) S100b as a prognostic biomarker in outcome prediction for patients with severe TBI. J Neurotrauma 30:946–957PubMedGoogle Scholar
  54. 54.
    Zurek J, Fedora M (2012) The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury. Acta Neurochir (Wien) 154:93–103; discussion 103Google Scholar
  55. 55.
    Nylen K, Ost M, Csajbok LZ, Nilsson I, Hall C, Blennow K, Nellgard B, Rosengren L (2008) Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien) 150:221–227; discussion 227Google Scholar
  56. 56.
    Tavarez MM, Atabaki SM, Teach SJ (2012) Acute evaluation of pediatric patients with minor traumatic brain injury. Curr Opin Pediatr 24:307–313PubMedGoogle Scholar
  57. 57.
    Bouvier D, Fournier M, Dauphin JB, Amat F, Ughetto S, Labbe A, Sapin V (2012) Serum S100B determination in the management of pediatric mild traumatic brain injury. Clin Chem 58:1116–1122PubMedGoogle Scholar
  58. 58.
    Lange RT, Iverson GL, Brubacher JR (2012) Clinical utility of the protein S100B to evaluate traumatic brain injury in the presence of acute alcohol intoxication. J Head Trauma Rehabil 27:123–134PubMedGoogle Scholar
  59. 59.
    Bloomfield SM, Mckinney J, Smith L, Brisman J (2007) Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care 6:121–138PubMedGoogle Scholar
  60. 60.
    Goncalves CA, Leite MC, Nardin P (2008) Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 41:755–763PubMedGoogle Scholar
  61. 61.
    Amick JE, Yandora KA, Bell MJ, Wisniewski SR, Adelson PD, Carcillo JA, Janesko KL, Dekosky ST, Carlos TM, Clark RS, Kochanek PM (2001) The Th1 versus Th2 cytokine profile in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatr Crit Care Med 2:260–264PubMedGoogle Scholar
  62. 62.
    Mussack T, Kirchhoff C, Buhmann S, Biberthaler P, Ladurner R, Gippner-Steppert C, Mutschler W, Jochum M (2006) Significance of Elecsys S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients. Clin Chem Lab Med 44:1140–1145PubMedGoogle Scholar
  63. 63.
    Romner B, Ingebrigtsen T (2001) High serum S100B levels for trauma patients without head injuries. Neurosurgery 49:1490; author reply 1492–1493PubMedGoogle Scholar
  64. 64.
    Rothoerl RD, Woertgen C (2001) High serum S100B levels for trauma patients without head injuries. Neurosurgery 49:1490–1491; author reply 1492–1493PubMedGoogle Scholar
  65. 65.
    Jonsson H, Johnsson P, Backstrom M, Alling C, Dautovic-Bergh C, Blomquist S (2004) Controversial significance of early S100B levels after cardiac surgery. BMC Neurol 4:24PubMedGoogle Scholar
  66. 66.
    Routsi C, Stamataki E, Nanas S, Psachoulia C, Stathopoulos A, Koroneos A, Zervou M, Jullien G, Roussos C (2006) Increased levels of serum S100B protein in critically ill patients without brain injury. Shock 26:20–24PubMedGoogle Scholar
  67. 67.
    Gonzclez-Mao MC, Reparaz-Andrade A, Del Campo-Perez V, Alvarez-Garcia E, Vara-Perez C, Andrade-Olivie MA (2011) Model predicting survival/exitus after traumatic brain injury: biomarker S100B 24h. Clin Lab 57:587–597PubMedGoogle Scholar
  68. 68.
    Berger RP, Adelson PD, Richichi R, Kochanek PM (2006) Serum biomarkers after traumatic and hypoxemic brain injuries: insight into the biochemical response of the pediatric brain to inflicted brain injury. Dev Neurosci 28:327–335PubMedGoogle Scholar
  69. 69.
    Berger RP, Dulani T, Adelson PD, Leventhal JM, Richichi R, Kochanek PM (2006) Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: a possible screening tool. Pediatrics 117:325–332PubMedGoogle Scholar
  70. 70.
    Piazza O, Storti MP, Cotena S, Stoppa F, Perrotta D, Esposito G, Pirozzi N, Tufano R (2007) S100B is not a reliable prognostic index in paediatric TBI. Pediatr Neurosurg 43:258–264PubMedGoogle Scholar
  71. 71.
    Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res 25:1439–1451PubMedGoogle Scholar
  72. 72.
    Eng LF, Vanderhaeghen JJ, Bignami A, Gerstl B (1971) An acidic protein isolated from fibrous astrocytes. Brain Res 28:351–354PubMedGoogle Scholar
  73. 73.
    Schiff L, Hadker N, Weiser S, Rausch C (2012) A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury. Mol Diagn Ther 16:79–92PubMedGoogle Scholar
  74. 74.
    Missler U, Wiesmann M, Wittmann G, Magerkurth O, Hagenstrom H (1999) Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem 45:138–141PubMedGoogle Scholar
  75. 75.
    Pelinka LE, Kroepfl A, Schmidhammer R, Krenn M, Buchinger W, Redl H, Raabe A (2004) Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma 57:1006–1012PubMedGoogle Scholar
  76. 76.
    van Geel WJ, de Reus HP, Nijzing H, Verbeek MM, Vos PE, Lamers KJ (2002) Measurement of glial fibrillary acidic protein in blood: an analytical method. Clin Chim Acta 326:151–154PubMedGoogle Scholar
  77. 77.
    Mondello S, Jeromin A, Buki A, Bullock R, Czeiter E, Kovacs N, Barzo P, Schmid K, Tortella F, Wang KK, Hayes RL (2011) Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. J Neurotrauma 29:1096–1104Google Scholar
  78. 78.
    O’Callaghan JP, Sriram K (2005) Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin Drug Saf 4:433–442PubMedGoogle Scholar
  79. 79.
    Papa L, Lewis LM, Falk JL, Zhang Z, Silvestri S, Giordano P, Brophy GM, Demery JA, Dixit NK, Ferguson I, Liu MC, Mo J, Akinyi L, Schmid K, Mondello S, Robertson CS, Tortella FC, Hayes RL, Wang KK (2011) Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med 59:471–483PubMedGoogle Scholar
  80. 80.
    Nylen K, Ost M, Csajbok LZ, Nilsson I, Blennow K, Nellgard B, Rosengren L (2006) Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci 240:85–91PubMedGoogle Scholar
  81. 81.
    Honda M, Tsuruta R, Kaneko T, Kasaoka S, Yagi T, Todani M, Fujita M, Izumi T, Maekawa T (2010) Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic brain injury in humans compared with S-100B and neuron-specific enolase. J Trauma 69:104–109PubMedGoogle Scholar
  82. 82.
    Fraser DD, Close TE, Rose KL, Ward R, Mehl M, Farrell C, Lacroix J, Creery D, Kesselman M, Stanimirovic D, Hutchison JS, Canadian Critical Care Translational Biology Group (2011) Severe traumatic brain injury in children elevates glial fibrillary acidic protein in cerebrospinal fluid and serum. Pediatr Crit Care Med 12:319–324PubMedGoogle Scholar
  83. 83.
    Hayes RL, Mondello S, Wang K (2011) Glial fibrillary acidic protein: a promising biomarker in pediatric brain injury. Pediatr Crit Care Med 12:603–604PubMedGoogle Scholar
  84. 84.
    Palfreyman JW, Thomas DG, Ratcliffe JG (1978) Radioimmunoassay of human myelin basic protein in tissue extract, cerebrospinal fluid and serum and its clinical application to patients with head injury. Clin Chim Acta 82:259–270PubMedGoogle Scholar
  85. 85.
    Thomas DG, Palfreyman JW, Ratcliffe JG (1978) Serum-myelin-basic-protein assay in diagnosis and prognosis of patients with head injury. Lancet 1:113–115PubMedGoogle Scholar
  86. 86.
    Thomas DG, Rabow L, Teasdale G (1979) Serum myelin basic protein, clinical responsiveness, and outcome of severe head injury. Acta Neurochir Suppl (Wien) 28:93–95Google Scholar
  87. 87.
    Rostami E, Davidsson J, Ng KC, Lu J, Gyorgy A, Walker J, Wingo D, Plantman S, Bellander BM, Agoston DV, Risling M (2012) A model for mild traumatic brain injury that induces limited transient memory impairment and increased levels of axon related serum biomarkers. Front Neurol 3:115PubMedGoogle Scholar
  88. 88.
    Marangos PJ, Schmechel DE (1987) Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci 10:269–295PubMedGoogle Scholar
  89. 89.
    Skogseid IM, Nordby HK, Urdal P, Paus E, Lilleaas F (1992) Increased serum creatine kinase BB and neuron specific enolase following head injury indicates brain damage. Acta Neurochir (Wien) 115:106–111Google Scholar
  90. 90.
    Bandyopadhyay S, Hennes H, Gorelick MH, Wells RG, Walsh-Kelly CM (2005) Serum neuron-specific enolase as a predictor of short-term outcome in children with closed traumatic brain injury. Acad Emerg Med 12:732–738PubMedGoogle Scholar
  91. 91.
    Beers SR, Berger RP, Adelson PD (2007) Neurocognitive outcome and serum biomarkers in inflicted versus non-inflicted traumatic brain injury in young children. J Neurotrauma 24:97–105PubMedGoogle Scholar
  92. 92.
    Fridriksson T, Kini N, Walsh-Kelly C, Hennes H (2000) Serum neuron-specific enolase as a predictor of intracranial lesions in children with head trauma: a pilot study. Acad Emerg Med 7:816–820PubMedGoogle Scholar
  93. 93.
    Ross SA, Cunningham RT, Johnston CF, Rowlands BJ (1996) Neuron-specific enolase as an aid to outcome prediction in head injury. Br J Neurosurg 10:471–476PubMedGoogle Scholar
  94. 94.
    Kochanek PM, Berger RP, Bayir H, Wagner AK, Jenkins LW, Clark RS (2008) Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: diagnosis, prognosis, probing mechanisms, and therapeutic decision making. Curr Opin Crit Care 14:135–141PubMedGoogle Scholar
  95. 95.
    Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I, Edman A, Popa C, Rasulzada A, Wahlund LO, Mehta PD, Rosengren L, Blennow K, Wallin A (2006) Neurochemical aftermath of amateur boxing. Arch Neurol 63:1277–1280PubMedGoogle Scholar
  96. 96.
    Zetterberg H, Tanriverdi F, Unluhizarci K, Selcuklu A, Kelestimur F, Blennow K (2009) Sustained release of neuron-specific enolase to serum in amateur boxers. Brain Inj 23:723–726PubMedGoogle Scholar
  97. 97.
    Stalnacke BM, Sojka P (2008) [S100B for diagnosis and prognosis of sequelae following minor head injury. Contradictory results according to studies]. Lakartidningen 105:1840–1845PubMedGoogle Scholar
  98. 98.
    Yamazaki Y, Yada K, Morii S, Kitahara T, Ohwada T (1995) Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg Neurol 43:267–270; discussion 270–271PubMedGoogle Scholar
  99. 99.
    Pelinka LE, Hertz H, Mauritz W, Harada N, Jafarmadar M, Albrecht M, Redl H, Bahrami S (2005) Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings. Shock 24:119–123PubMedGoogle Scholar
  100. 100.
    Pelinka LE, Jafarmadar M, Redl H, Bahrami S (2004) Neuron-specific-enolase is increased in plasma after hemorrhagic shock and after bilateral femur fracture without traumatic brain injury in the rat. Shock 22:88–91PubMedGoogle Scholar
  101. 101.
    Day IN, Thompson RJ (2010) UCHL1 (PGP 9.5): neuronal biomarker and ubiquitin system protein. Prog Neurobiol 90:327–362PubMedGoogle Scholar
  102. 102.
    Gong B, Leznik E (2007) The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect 20:365–370PubMedGoogle Scholar
  103. 103.
    Tongaonkar P, Chen L, Lambertson D, Ko B, Madura K (2000) Evidence for an interaction between ubiquitin-conjugating enzymes and the 26S proteasome. Mol Cell Biol 20:4691–4698PubMedGoogle Scholar
  104. 104.
    Liu MC, Akinyi L, Scharf D, Mo J, Larner SF, Muller U, Oli MW, Zheng W, Kobeissy F, Papa L, Lu XC, Dave JR, Tortella FC, Hayes RL, Wang KK (2010) Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur J Neurosci 31:722–732PubMedGoogle Scholar
  105. 105.
    Blyth BJ, Farahvar A, He H, Nayak A, Yang C, Shaw G, Bazarian JJ (2011) Elevated serum ubiquitin carboxy-terminal hydrolase L1 is associated with abnormal blood–brain barrier function after traumatic brain injury. J Neurotrauma 28:2453–2462PubMedGoogle Scholar
  106. 106.
    Papa L, Akinyi L, Liu MC, Pineda JA, Tepas JJ III, Oli MW, Zheng W, Robinson G, Robicsek SA, Gabrielli A, Heaton SC, Hannay HJ, Demery JA, Brophy GM, Layon J, Robertson CS, Hayes RL, Wang KK (2010) Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 38:138–144PubMedGoogle Scholar
  107. 107.
    Brophy GM, Mondello S, Papa L, Robicsek SA, Gabrielli A, Tepas J III, Buki A, Robertson C, Tortella FC, Hayes RL, Wang KK (2011) Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma 28:861–870PubMedGoogle Scholar
  108. 108.
    Czeiter E, Mondello S, Kovacs N, Sandor J, Gabrielli A, Schmid K, Tortella F, Wang KK, Hayes RL, Barzo P, Ezer E, Doczi T, Buki A (2012) Brain injury biomarkers may improve the predictive power of the IMPACT outcome calculator. J Neurotrauma 29:1770–1778PubMedGoogle Scholar
  109. 109.
    Mondello S, Linnet A, Buki A, Robicsek S, Gabrielli A, Tepas J, Papa L, Brophy GM, Tortella F, Hayes RL, Wang KK (2012) Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. Neurosurgery 70:666–675PubMedGoogle Scholar
  110. 110.
    Papa L, Akinyi L, Liu MC, Pineda JA, Tepas JJIII, Oli MW, Zheng W, Robinson G, Robicsek SA, Gabrielli A, Heaton SC, Hannay HJ, Demery JA, Brophy GM, Layon J, Robertson CS, Hayes RL, Wang KK (2009) Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 38:138–144Google Scholar
  111. 111.
    Papa L, Lewis LM, Silvestri S, Falk JL, Giordano P, Brophy GM, Demery JA, Liu MC, Mo J, Akinyi L, Mondello S, Schmid K, Robertson CS, Tortella FC, Hayes RL, Wang KK (2012) Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. J Trauma Acute Care Surg 72:1335–1344PubMedGoogle Scholar
  112. 112.
    Papa L, Ramia MM, Kelly JM, Burks SS, Pawlowicz A, Berger RP (2013) Systematic review of clinical research on biomarkers for pediatric traumatic brain injury. J Neurotrauma 30:324–338PubMedGoogle Scholar
  113. 113.
    Mondello S, Gabrielli A, Catani S, D’ippolito M, Jeromin A, Ciaramella A, Bossu P, Schmid K, Tortella F, Wang KK, Hayes RL, Formisano R (2012) Increased levels of serum MAP-2 at 6-months correlate with improved outcome in survivors of severe traumatic brain injury. Brain Inj 26:1629–1635PubMedGoogle Scholar
  114. 114.
    Liu Q, Xie F, Siedlak SL, Nunomura A, Honda K, Moreira PI, Zhua X, Smith MA, Perry G (2004) Neurofilament proteins in neurodegenerative diseases. Cell Mol Life Sci 61:3057–3075PubMedGoogle Scholar
  115. 115.
    Anderson KJ, Scheff SW, Miller KM, Roberts KN, Gilmer LK, Yang C, Shaw G (2008) The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury. J Neurotrauma 25:1079–1085PubMedGoogle Scholar
  116. 116.
    Shaw G, Yang C, Ellis R, Anderson K, Parker Mickle J, Scheff S, Pike B, Anderson DK, Howland DR (2005) Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem Biophys Res Commun 336:1268–1277PubMedGoogle Scholar
  117. 117.
    Zurek J, Bartlova L, Fedora M (2011) Hyperphosphorylated neurofilament NF-H as a predictor of mortality after brain injury in children. Brain Inj 25:221–226PubMedGoogle Scholar
  118. 118.
    Hergenroeder G, Redell JB, Moore AN, Dubinsky WP, Funk RT, Crommett J, Clifton GL, Levine R, Valadka A, Dash PK (2008) Identification of serum biomarkers in brain-injured adults: potential for predicting elevated intracranial pressure. J Neurotrauma 25:79–93PubMedGoogle Scholar
  119. 119.
    Trojanowski JQ, Schuck T, Schmidt ML, Lee VM (1989) Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem 37:209–215PubMedGoogle Scholar
  120. 120.
    Mortberg E, Zetterberg H, Nordmark J, Blennow K, Catry C, Decraemer H, Vanmechelen E, Rubertsson S (2011) Plasma tau protein in comatose patients after cardiac arrest treated with therapeutic hypothermia. Acta Anaesthesiol Scand 55:1132–1138PubMedGoogle Scholar
  121. 121.
    Randall J, Mortberg E, Provuncher GK, Fournier DR, Duffy DC, Rubertsson S, Blennow K, Zetterberg H, Wilson DH (2013) Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation 84:351–356PubMedGoogle Scholar
  122. 122.
    Neselius S, Zetterberg H, Blennow K, Randall J, Wilson D, Marcusson J, Brisby H (2013) Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. Brain Inj 27:425–433PubMedGoogle Scholar
  123. 123.
    Riederer BM, Zagon IS, Goodman SR (1986) Brain spectrin(240/235) and brain spectrin(240/235E): two distinct spectrin subtypes with different locations within mammalian neural cells. J Cell Biol 102:2088–2097PubMedGoogle Scholar
  124. 124.
    Zhang Z, Larner SF, Liu MC, Zheng W, Hayes RL, Wang KK (2009) Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis 14:1289–1298PubMedGoogle Scholar
  125. 125.
    Pike BR, Flint J, Dutta S, Johnson E, Wang KK, Hayes RL (2001) Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J Neurochem 78:1297–1306PubMedGoogle Scholar
  126. 126.
    Pike BR, Zhao X, Newcomb JK, Posmantur RM, Wang KK, Hayes RL (1998) Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury. Neuroreport 9:2437–2442PubMedGoogle Scholar
  127. 127.
    Raghupathi R, Graham DI, Mcintosh TK (2000) Apoptosis after traumatic brain injury. J Neurotrauma 17:927–938PubMedGoogle Scholar
  128. 128.
    Saatman KE, Creed J, Raghupathi R (2010) Calpain as a therapeutic target in traumatic brain injury. Neurotherapeutics 7:31–42PubMedGoogle Scholar
  129. 129.
    Siman R, Mcintosh TK, Soltesz KM, Chen Z, Neumar RW, Roberts VL (2004) Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol Dis 16:311–320PubMedGoogle Scholar
  130. 130.
    Wang KK (2000) Calpain and caspase: can you tell the difference? Trends Neurosci 23:20–26PubMedGoogle Scholar
  131. 131.
    Zetterberg H, Smith DH, Blennow K (2013) Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol 9:201–210PubMedGoogle Scholar
  132. 132.
    Dash PK, Zhao J, Hergenroeder G, Moore AN (2010) Biomarkers for the diagnosis, prognosis and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics 7:100–114PubMedGoogle Scholar
  133. 133.
    Schmid KE, Tortella FC (2012) The diagnosis of traumatic brain injury on the battlefield. Front Neurol 3:90PubMedGoogle Scholar
  134. 134.
    Woodcock T, Morganti-Kossmann MC (2013) The role of markers of inflammation in traumatic brain injury. Front Neurol 4:18PubMedGoogle Scholar
  135. 135.
    Giulian D, Lachman LB (1985) Interleukin-1 stimulation of astroglial proliferation after brain injury. Science 228:497–499PubMedGoogle Scholar
  136. 136.
    Kossmann T, Hans V, Imhof HG, Trentz O, Morganti-Kossmann MC (1996) Interleukin-6 released in human cerebrospinal fluid following traumatic brain injury may trigger nerve growth factor production in astrocytes. Brain Res 713:143–152PubMedGoogle Scholar
  137. 137.
    Tasci A, Okay O, Gezici AR, Ergun R, Ergungor F (2003) Prognostic value of interleukin-1 beta levels after acute brain injury. Neurol Res 25:871–874PubMedGoogle Scholar
  138. 138.
    Hergenroeder GW, Redell JB, Moore AN, Dash PK (2008) Biomarkers in the clinical diagnosis and management of traumatic brain injury. Mol Diagn Ther 12:345–358PubMedGoogle Scholar
  139. 139.
    Jeter CB, Hergenroeder GW, Hylin MJ, Redell JB, Moore AN, Dash PK (2013) Biomarkers for the diagnosis and prognosis of mild traumatic brain injury/concussion. J Neurotrauma 30:657–670PubMedGoogle Scholar
  140. 140.
    Brenner T, Yamin A, Abramsky O, Gallily R (1993) Stimulation of tumor necrosis factor-alpha production by mycoplasmas and inhibition by dexamethasone in cultured astrocytes. Brain Res 608:273–279PubMedGoogle Scholar
  141. 141.
    Mier JW, Vachino G, van der Meer JW, Numerof RP, Adams S, Cannon JG, Bernheim HA, Atkins MB, Parkinson DR, Dinarello CA (1988) Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 8:426–436PubMedGoogle Scholar
  142. 142.
    Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T (1997) Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 72:169–177PubMedGoogle Scholar
  143. 143.
    Goodman JC, Robertson CS, Grossman RG, Narayan RK (1990) Elevation of tumor necrosis factor in head injury. J Neuroimmunol 30:213–217PubMedGoogle Scholar
  144. 144.
    Ross SA, Halliday MI, Campbell GC, Byrnes DP, Rowlands BJ (1994) The presence of tumour necrosis factor in CSF and plasma after severe head injury. Br J Neurosurg 8:419–425PubMedGoogle Scholar
  145. 145.
    Crespo AR, Da Rocha AB, Jotz GP, Schneider RF, Grivicich I, Pinheiro K, Zanoni C, Regner A (2007) Increased serum sFas and TNFalpha following isolated severe head injury in males. Brain Inj 21:441–447PubMedGoogle Scholar
  146. 146.
    Stein DM, Kufera JA, Lindell A, Murdock KR, Menaker J, Bochicchio GV, Aarabi B, Scalea TM (2011) Association of CSF biomarkers and secondary insults following severe traumatic brain injury. Neurocrit Care 14:200–207PubMedGoogle Scholar
  147. 147.
    Stein DM, Lindell A, Murdock KR, Kufera JA, Menaker J, Keledjian K, Bochicchio GV, Aarabi B, Scalea TM (2011) Relationship of serum and cerebrospinal fluid biomarkers with intracranial hypertension and cerebral hypoperfusion after severe traumatic brain injury. J Trauma 70:1096–1103PubMedGoogle Scholar
  148. 148.
    Hohl A, Gullo Jda S, Silva CC, Bertotti MM, Felisberto F, Nunes JC, de Souza B, Petronilho F, Soares FM, Prediger RD, Dal-Pizzol F, Linhares MN, Walz R (2012) Plasma levels of oxidative stress biomarkers and hospital mortality in severe head injury: a multivariate analysis. J Crit Care 27(523):e11–e19PubMedGoogle Scholar
  149. 149.
    Balakathiresan N, Bhomia M, Chandran R, Chavko M, Mccarron RM, Maheshwari RK (2012) MicroRNA let-7i is a promising serum biomarker for blast-induced traumatic brain injury. J Neurotrauma 29:1379–1387PubMedGoogle Scholar
  150. 150.
    Chittiboina P, Ganta V, Monceaux CP, Scott LK, Nanda A, Alexander JS (2013) Angiopoietins as promising biomarkers and potential therapeutic targets in brain injury. Pathophysiology 20:15–21PubMedGoogle Scholar
  151. 151.
    Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RS, Ruppel RA, Kochanek PM (2002) Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics 109:E31PubMedGoogle Scholar
  152. 152.
    Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J (2012) CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One 7:e33606PubMedGoogle Scholar
  153. 153.
    Bohmer AE, Oses JP, Schmidt AP, Peron CS, Krebs CL, Oppitz PP, D’avila TT, Souza DO, Portela LV, Stefani MA (2011) Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury. Neurosurgery 68:1624–1630; discussion 1630–1631PubMedGoogle Scholar
  154. 154.
    Bellander BM, Olafsson IH, Ghatan PH, Bro Skejo HP, Hansson LO, Wanecek M, Svensson MA (2011) Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. Acta Neurochir (Wien) 153:90–100Google Scholar
  155. 155.
    Niyonkuru C, Wagner AMD, Ozawa H, Amin K, Goyal A, Fabio A (2013) Group based trajectory analysis applications for prognostic biomarker model development in severe TBI: a practical example. J Neurotrauma 30:938–945PubMedGoogle Scholar
  156. 156.
    Ahmed F, Gyorgy A, Kamnaksh A, Ling G, Tong L, Parks S, Agoston D (2012) Time-dependent changes of protein biomarker levels in the cerebrospinal fluid after blast traumatic brain injury. Electrophoresis 33:3705–3711PubMedGoogle Scholar
  157. 157.
    Zoltewicz JS, Mondello S, Yang B, Newsom KJ, Kobeissy FH, Yao C, Lu XC, Dave JR, Shear DA, Schmid K, Rivera V, Cram T, Seaney J, Zhang Z, Wang KK, Hayes RL, Tortella FC (2013) Biomarkers track damage following graded injury severity in a rat model of penetrating brain injury. J Neurotrauma 30:1161–1169PubMedGoogle Scholar
  158. 158.
    Zoltewicz JS, Scharf D, Yang B, Chawla A, Newsom KJ, Fang L (2012) Characterization of antibodies that detect human GFAP after traumatic brain injury. Biomark Insights 7:71–79PubMedGoogle Scholar
  159. 159.
    Berger RP (2006) The use of serum biomarkers to predict outcome after traumatic brain injury in adults and children. J Head Trauma Rehabil 21:315–333PubMedGoogle Scholar
  160. 160.
    Chiaretti A, Barone G, Riccardi R, Antonelli A, Pezzotti P, Genovese O, Tortorolo L, Conti G (2009) NGF, DCX, and NSE upregulation correlates with severity and outcome of head trauma in children. Neurology 72:609–616PubMedGoogle Scholar
  161. 161.
    Scarna H, Delafosse B, Steinberg R, Debilly G, Mandrand B, Keller A, Pujol JF (1982) Neuron-specific enolase as a marker of neuronal lesions during various comas in man. Neurochem Int 4:405–411PubMedGoogle Scholar
  162. 162.
    Siman R, Toraskar N, Dang A, Mcneil E, Mcgarvey M, Plaum J, Maloney E, Grady MS (2009) A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma 26:1867–1877PubMedGoogle Scholar
  163. 163.
    Varma S, Janesko KL, Wisniewski SR, Bayir H, Adelson PD, Thomas NJ, Kochanek PM (2003) F2-isoprostane and neuron-specific enolase in cerebrospinal fluid after severe traumatic brain injury in infants and children. J Neurotrauma 20:781–786PubMedGoogle Scholar
  164. 164.
    Mondello S, Jeromin A, Buki A, Bullock R, Czeiter E, Kovacs N, Barzo P, Schmid K, Tortella F, Wang KK, Hayes RL (2012) Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. J Neurotrauma 29:1096–1104PubMedGoogle Scholar
  165. 165.
    Mondello S, Palmio J, Streeter J, Hayes RL, Peltola J, Jeromin A (2012) Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure. BMC Neurol 12:85PubMedGoogle Scholar
  166. 166.
    Friede RL, Samorajski T (1970) Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat Rec 167:379–387PubMedGoogle Scholar
  167. 167.
    Blennow K, Hardy J, Zetterberg H (2012) The neuropathology and neurobiology of traumatic brain injury. Neuron 76:886–899PubMedGoogle Scholar
  168. 168.
    Grady MS, Mclaughlin MR, Christman CW, Valadka AB, Fligner CL, Povlishock JT (1993) The use of antibodies targeted against the neurofilament subunits for the detection of diffuse axonal injury in humans. J Neuropathol Exp Neurol 52:143–152PubMedGoogle Scholar
  169. 169.
    Olsson B, Zetterberg H, Hampel H, Blennow K (2011) Biomarker-based dissection of neurodegenerative diseases. Prog Neurobiol 95:520–534PubMedGoogle Scholar
  170. 170.
    Blennow K, Nellgard B (2004) Amyloid beta 1–42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 62:159; author reply 159–160PubMedGoogle Scholar
  171. 171.
    Franz G, Beer R, Kampfl A, Engelhardt K, Schmutzhard E, Ulmer H, Deisenhammer F (2003) Amyloid beta 1–42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 60:1457–1461PubMedGoogle Scholar
  172. 172.
    Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG, Zuccarello M (2002) C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res 947:131–139PubMedGoogle Scholar
  173. 173.
    Ost M, Nylen K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelso C, Nellgard P, Rosengren L, Blennow K, Nellgard B (2006) Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67:1600–1604PubMedGoogle Scholar
  174. 174.
    Gentleman SM, Nash MJ, Sweeting CJ, Graham DI, Roberts GW (1993) Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. Neurosci Lett 160:139–144PubMedGoogle Scholar
  175. 175.
    Gentleman SM, Roberts GW, Gennarelli TA, Maxwell WL, Adams JH, Kerr S, Graham DI (1995) Axonal injury: a universal consequence of fatal closed head injury? Acta Neuropathol 89:537–543PubMedGoogle Scholar
  176. 176.
    Graham DI, Adams JH, Nicoll JA, Maxwell WL, Gennarelli TA (1995) The nature, distribution and causes of traumatic brain injury. Brain Pathol 5:397–406PubMedGoogle Scholar
  177. 177.
    Graham DI, Gentleman SM, Lynch A, Roberts GW (1995) Distribution of beta-amyloid protein in the brain following severe head injury. Neuropathol Appl Neurobiol 21:27–34PubMedGoogle Scholar
  178. 178.
    Horsburgh K, Cole GM, Yang F, Savage MJ, Greenberg BD, Gentleman SM, Graham DI, Nicoll JA (2000) Beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injury. Neuropathol Appl Neurobiol 26:124–132PubMedGoogle Scholar
  179. 179.
    Mckenzie JE, Gentleman SM, Roberts GW, Graham DI, Royston MC (1994) Increased numbers of beta APP-immunoreactive neurones in the entorhinal cortex after head injury. Neuroreport 6:161–164PubMedGoogle Scholar
  180. 180.
    Mckenzie KJ, Mclellan DR, Gentleman SM, Maxwell WL, Gennarelli TA, Graham DI (1996) Is beta-APP a marker of axonal damage in short-surviving head injury? Acta Neuropathol 92:608–613PubMedGoogle Scholar
  181. 181.
    Roberts GW, Gentleman SM, Lynch A, Graham DI (1991) Beta A4 amyloid protein deposition in brain after head trauma. Lancet 338:1422–1423PubMedGoogle Scholar
  182. 182.
    Sherriff FE, Bridges LR, Gentleman SM, Sivaloganathan S, Wilson S (1994) Markers of axonal injury in post mortem human brain. Acta Neuropathol 88:433–439PubMedGoogle Scholar
  183. 183.
    Sherriff FE, Bridges LR, Sivaloganathan S (1994) Early detection of axonal injury after human head trauma using immunocytochemistry for beta-amyloid precursor protein. Acta Neuropathol 87:55–62PubMedGoogle Scholar
  184. 184.
    Smith DH, Chen XH, Iwata A, Graham DI (2003) Amyloid beta accumulation in axons after traumatic brain injury in humans. J Neurosurg 98:1072–1077PubMedGoogle Scholar
  185. 185.
    Smith DH, Chen XH, Nonaka M, Trojanowski JQ, Lee VM, Saatman KE, Leoni MJ, Xu BN, Wolf JA, Meaney DF (1999) Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. J Neuropathol Exp Neurol 58:982–992PubMedGoogle Scholar
  186. 186.
    Smith DH, Uryu K, Saatman KE, Trojanowski JQ, Mcintosh TK (2003) Protein accumulation in traumatic brain injury. Neuromolecular Med 4:59–72PubMedGoogle Scholar
  187. 187.
    Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DI, Lee VM, Trojanowski JQ, Smith DH (2007) Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol 208:185–192PubMedGoogle Scholar
  188. 188.
    Chen XH, Johnson VE, Uryu K, Trojanowski JQ, Smith DH (2009) A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol 19:214–223PubMedGoogle Scholar
  189. 189.
    Olsson A, Csajbok L, Ost M, Hoglund K, Nylen K, Rosengren L, Nellgard B, Blennow K (2004) Marked increase of beta-amyloid(1–42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J Neurol 251:870–876PubMedGoogle Scholar
  190. 190.
    Raby CA, Morganti-Kossmann MC, Kossmann T, Stahel PF, Watson MD, Evans LM, Mehta PD, Spiegel K, Kuo YM, Roher AE, Emmerling MR (1998) Traumatic brain injury increases beta-amyloid peptide 1–42 in cerebrospinal fluid. J Neurochem 71:2505–2509PubMedGoogle Scholar
  191. 191.
    Mondello S, Buki A, Italiano D, Jeromin A (2013) Alpha-synuclein in CSF of patients with severe traumatic brain injury. Neurology 80:1662–1668PubMedGoogle Scholar
  192. 192.
    Farkas O, Polgar B, Szekeres-Bartho J, Doczi T, Povlishock JT, Buki A (2005) Spectrin breakdown products in the cerebrospinal fluid in severe head injury–preliminary observations. Acta Neurochir (Wien) 147:855–861Google Scholar
  193. 193.
    Pineda JA, Lewis SB, Valadka AB, Papa L, Hannay HJ, Heaton SC, Demery JA, Liu MC, Aikman JM, Akle V, Brophy GM, Tepas JJ, Wang KK, Robertson CS, Hayes RL (2007) Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma 24:354–366PubMedGoogle Scholar
  194. 194.
    Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T (1999) IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood–brain barrier function. J Neuroimmunol 101:211–221PubMedGoogle Scholar
  195. 195.
    Mondello S, Robicsek SA, Gabrielli A, Brophy GM, Papa L, Tepas J, Robertson C, Buki A, Scharf D, Jixiang M, Akinyi L, Muller U, Wang KK, Hayes RL (2010) AlphaII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma 27:1203–1213PubMedGoogle Scholar
  196. 196.
    Tibbling G, Link H, Ohman S (1977) Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 37:385–390PubMedGoogle Scholar
  197. 197.
    Kossmann T, Hans VH, Imhof HG, Stocker R, Grob P, Trentz O, Morganti-Kossmann C (1995) Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock 4:311–317PubMedGoogle Scholar
  198. 198.
    Mcclain C, Cohen D, Phillips R, Ott L, Young B (1991) Increased plasma and ventricular fluid interleukin-6 levels in patients with head injury. J Lab Clin Med 118:225–231PubMedGoogle Scholar
  199. 199.
    Mcclain CJ, Cohen D, Ott L, Dinarello CA, Young B (1987) Ventricular fluid interleukin-1 activity in patients with head injury. J Lab Clin Med 110:48–54PubMedGoogle Scholar
  200. 200.
    Singhal A, Baker AJ, Hare GM, Reinders FX, Schlichter LC, Moulton RJ (2002) Association between cerebrospinal fluid interleukin-6 concentrations and outcome after severe human traumatic brain injury. J Neurotrauma 19:929–937PubMedGoogle Scholar
  201. 201.
    Chiaretti A, Genovese O, Aloe L, Antonelli A, Piastra M, Polidori G, Di Rocco C (2005) Interleukin 1beta and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv Syst 21:185–193; discussion 194PubMedGoogle Scholar
  202. 202.
    Hayakata T, Shiozaki T, Tasaki O, Ikegawa H, Inoue Y, Toshiyuki F, Hosotubo H, Kieko F, Yamashita T, Tanaka H, Shimazu T, Sugimoto H (2004) Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock 22:102–107PubMedGoogle Scholar
  203. 203.
    Shiozaki T, Hayakata T, Tasaki O, Hosotubo H, Fuijita K, Mouri T, Tajima G, Kajino K, Nakae H, Tanaka H, Shimazu T, Sugimoto H (2005) Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury. Shock 23:406–410PubMedGoogle Scholar
  204. 204.
    Rasouli J, Lekhraj R, White NM, Flamm ES, Pilla AA, Strauch B, Casper D (2012) Attenuation of interleukin-1beta by pulsed electromagnetic fields after traumatic brain injury. Neurosci Lett 519:4–8PubMedGoogle Scholar
  205. 205.
    Chiaretti A, Antonelli A, Mastrangelo A, Pezzotti P, Tortorolo L, Tosi F, Genovese O (2008) Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J Neurotrauma 25:225–234PubMedGoogle Scholar
  206. 206.
    Bell MJ, Kochanek PM, Doughty LA, Carcillo JA, Adelson PD, Clark RS, Whalen MJ, Dekosky ST (1997) Comparison of the interleukin-6 and interleukin-10 response in children after severe traumatic brain injury or septic shock. Acta Neurochir Suppl 70:96–97PubMedGoogle Scholar
  207. 207.
    Bell MJ, Kochanek PM, Doughty LA, Carcillo JA, Adelson PD, Clark RS, Wisniewski SR, Whalen MJ, Dekosky ST (1997) Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children. J Neurotrauma 14:451–457PubMedGoogle Scholar
  208. 208.
    Buttram SD, Wisniewski SR, Jackson EK, Adelson PD, Feldman K, Bayir H, Berger RP, Clark RS, Kochanek PM (2007) Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: effects of moderate hypothermia. J Neurotrauma 24:1707–1717PubMedGoogle Scholar
  209. 209.
    Clark RS, Carcillo JA, Kochanek PM, Obrist WD, Jackson EK, Mi Z, Wisneiwski SR, Bell MJ, Marion DW (1997) Cerebrospinal fluid adenosine concentration and uncoupling of cerebral blood flow and oxidative metabolism after severe head injury in humans. Neurosurgery 41:1284–1292; discussion 1292–1293PubMedGoogle Scholar
  210. 210.
    Goodman JC, Van M, Gopinath SP, Robertson CS (2008) Pro-inflammatory and pro-apoptotic elements of the neuroinflammatory response are activated in traumatic brain injury. Acta Neurochir Suppl 102:437–439PubMedGoogle Scholar
  211. 211.
    Kirchhoff C, Buhmann S, Bogner V, Stegmaier J, Leidel BA, Braunstein V, Mutschler W, Biberthaler P (2008) Cerebrospinal IL-10 concentration is elevated in non-survivors as compared to survivors after severe traumatic brain injury. Eur J Med Res 13:464–468PubMedGoogle Scholar
  212. 212.
    Maier B, Lehnert M, Laurer HL, Mautes AE, Steudel WI, Marzi I (2006) Delayed elevation of soluble tumor necrosis factor receptors p75 and p55 in cerebrospinal fluid and plasma after traumatic brain injury. Shock 26:122–127PubMedGoogle Scholar
  213. 213.
    Phillips DJ, Nguyen P, Adamides AA, Bye N, Rosenfeld JV, Kossmann T, Vallance S, Murray L, Morganti-Kossmann MC (2006) Activin a release into cerebrospinal fluid in a subset of patients with severe traumatic brain injury. J Neurotrauma 23:1283–1294PubMedGoogle Scholar
  214. 214.
    Semple BD, Bye N, Rancan M, Ziebell JM, Morganti-Kossmann MC (2010) Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2−/− mice. J Cereb Blood Flow Metab 30:769–782PubMedGoogle Scholar
  215. 215.
    Stahel PF, Morganti-Kossmann MC, Perez D, Redaelli C, Gloor B, Trentz O, Kossmann T (2001) Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood–brain barrier dysfunction in patients with traumatic brain injury. J Neurotrauma 18:773–781PubMedGoogle Scholar
  216. 216.
    Whalen MJ, Carlos TM, Kochanek PM, Wisniewski SR, Bell MJ, Clark RS, Dekosky ST, Marion DW, Adelson PD (2000) Interleukin-8 is increased in cerebrospinal fluid of children with severe head injury. Crit Care Med 28:929–934PubMedGoogle Scholar
  217. 217.
    Zedler S, Faist E (2006) The impact of endogenous triggers on trauma-associated inflammation. Curr Opin Crit Care 12:595–601PubMedGoogle Scholar
  218. 218.
    Morganti-Kossmann MC, Rancan M, Stahel PF, Kossmann T (2002) Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr Opin Crit Care 8:101–105PubMedGoogle Scholar
  219. 219.
    Morganti-Kossmann MC, Hans VH, Lenzlinger PM, Dubs R, Ludwig E, Trentz O, Kossmann T (1999) TGF-beta is elevated in the CSF of patients with severe traumatic brain injuries and parallels blood–brain barrier function. J Neurotrauma 16:617–628PubMedGoogle Scholar
  220. 220.
    Bayir H, Kagan VE, Tyurina YY, Tyurin V, Ruppel RA, Adelson PD, Graham SH, Janesko K, Clark RS, Kochanek PM (2002) Assessment of antioxidant reserves and oxidative stress in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatr Res 51:571–578PubMedGoogle Scholar
  221. 221.
    Bayir H, Kochanek PM, Clark RS (2003) Traumatic brain injury in infants and children: mechanisms of secondary damage and treatment in the intensive care unit. Crit Care Clin 19:529–549PubMedGoogle Scholar
  222. 222.
    Bayir H, Kochanek PM, Liu SX, Arroyo A, Osipov A, Jiang J, Wisniewski S, Adelson PD, Graham SH, Kagan VE (2003) Increased S-nitrosothiols and S-nitrosoalbumin in cerebrospinal fluid after severe traumatic brain injury in infants and children: indirect association with intracranial pressure. J Cereb Blood Flow Metab 23:51–61PubMedGoogle Scholar
  223. 223.
    Clark RS, Kochanek PM, Adelson PD, Bell MJ, Carcillo JA, Chen M, Wisniewski SR, Janesko K, Whalen MJ, Graham SH (2000) Increases in bcl-2 protein in cerebrospinal fluid and evidence for programmed cell death in infants and children after severe traumatic brain injury. J Pediatr 137:197–204PubMedGoogle Scholar
  224. 224.
    Clark RS, Kochanek PM, Watkins SC, Chen M, Dixon CE, Seidberg NA, Melick J, Loeffert JE, Nathaniel PD, Jin KL, Graham SH (2000) Caspase-3 mediated neuronal death after traumatic brain injury in rats. J Neurochem 74:740–753PubMedGoogle Scholar
  225. 225.
    Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA (2009) Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery 65:702–708PubMedGoogle Scholar
  226. 226.
    Robertson CL, Minamino N, Ruppel RA, Kangawa K, Wisniewski SR, Tsuji T, Janesko KL, Ohta H, Adelson PD, Marion DW, Kochanek PM (2001) Increased adrenomedullin in cerebrospinal fluid after traumatic brain injury in infants and children. J Neurotrauma 18:861–868PubMedGoogle Scholar
  227. 227.
    Satchell MA, Zhang X, Kochanek PM, Dixon CE, Jenkins LW, Melick J, Szabo C, Clark RS (2003) A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD+ depletion and ribosylation of 14-3-3gamma. J Neurochem 85:697–708PubMedGoogle Scholar
  228. 228.
    Darwish RS, Amiridze NS (2010) Detectable levels of cytochrome C and activated caspase-9 in cerebrospinal fluid after human traumatic brain injury. Neurocrit Care 12:337–341PubMedGoogle Scholar
  229. 229.
    Wagner AK (2010) TBI translational rehabilitation research in the 21st Century: exploring a Rehabilomics research model. Eur J Phys Rehabil Med 46:549–556PubMedGoogle Scholar
  230. 230.
    Wagner AK, Mccullough EH, Niyonkuru C, Ozawa H, Loucks TL, Dobos JA, Brett CA, Santarsieri M, Dixon CE, Berga SL, Fabio A (2011) Acute serum hormone levels: characterization and prognosis after severe traumatic brain injury. J Neurotrauma 28:871–888PubMedGoogle Scholar
  231. 231.
    Au AK, Aneja RK, Bell MJ, Bayir H, Feldman K, Adelson PD, Fink EL, Kochanek PM, Clark RS (2012) Cerebrospinal fluid levels of high-mobility group box 1 and cytochrome C predict outcome after pediatric traumatic brain injury. J Neurotrauma 29:2013–2021PubMedGoogle Scholar
  232. 232.
    Adamczak S, Dale G, de Rivero Vaccari JP, Bullock MR, Dietrich WD, Keane RW (2012) Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article. J Neurosurg 117:1119–1125PubMedGoogle Scholar
  233. 233.
    Johnston SC, Mendis S, Mathers CD (2009) Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurol 8:345–354PubMedGoogle Scholar
  234. 234.
    Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, Mcdermott M, Meigs J, Moy C, Nichol G, O’donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y (2008) Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25–e146PubMedGoogle Scholar
  235. 235.
    Montaner J (2006) Stroke biomarkers: can they help us to guide stroke thrombolysis? Drug News Perspect 19:523–532PubMedGoogle Scholar
  236. 236.
    Castellanos M, Serena J (2007) Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis 24(suppl 1):7–15PubMedGoogle Scholar
  237. 237.
    Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, Leira R, Lizasoain I, Castillo J, Davalos A (2005) The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 36:1921–1926PubMedGoogle Scholar
  238. 238.
    Pike BR, Flint J, Dave JR, Lu XC, Wang KK, Tortella FC, Hayes RL (2004) Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 24:98–106PubMedGoogle Scholar
  239. 239.
    Zhang C, Siman R, Xu YA, Mills AM, Frederick JR, Neumar RW (2002) Comparison of calpain and caspase activities in the adult rat brain after transient forebrain ischemia. Neurobiol Dis 10:289–295PubMedGoogle Scholar
  240. 240.
    Mattson MP, Keller JN, Begley JG (1998) Evidence for synaptic apoptosis. Exp Neurol 153:35–48PubMedGoogle Scholar
  241. 241.
    Posmantur RM, Kampfl A, Taft WC, Bhattacharjee M, Dixon CE, Bao J, Hayes RL (1996) Diminished microtubule-associated protein 2 (MAP2) immunoreactivity following cortical impact brain injury. J Neurotrauma 13:125–137PubMedGoogle Scholar
  242. 242.
    Taft WC, Yang K, Dixon CE, Hayes RL (1992) Microtubule-associated protein 2 levels decrease in hippocampus following traumatic brain injury. J Neurotrauma 9:281–290PubMedGoogle Scholar
  243. 243.
    Allard L et al (2005) PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem 51(11):2043–2051PubMedGoogle Scholar
  244. 244.
    Yao C et al (2009) P43/pro-EMAPII: a potential biomarker for discriminating traumatic versus ischemic brain injury. J Neurotrauma 26(8):1295–1305PubMedGoogle Scholar
  245. 245.
    Yao X, Liu J, Mccabe JT (2008) Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a TBI rat model. J Neurochem 104(2):353–363PubMedGoogle Scholar
  246. 246.
    Lakhan SE, Kirchgessner A, Hofer M (2009) Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 7:97PubMedGoogle Scholar
  247. 247.
    Hochholzer W, Morrow DA, Giugliano RP (2010) Novel biomarkers in cardiovascular disease. Am Heart J 160(4):538–594Google Scholar
  248. 248.
    Singh D et al (2010) Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res 11:77PubMedGoogle Scholar
  249. 249.
    Berger RP et al (2007) Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J Neurotrauma 24(12):1793–1801PubMedGoogle Scholar
  250. 250.
    Donnan GA et al (2011) How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol 7(7):400–409PubMedGoogle Scholar
  251. 251.
    Whitleley W, Tseng MC, Sandercock P (2008) Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke 39(10):2902–2909Google Scholar
  252. 252.
    Kavalci C et al (2011) Value of biomarker-based diagnostic test in differential diagnosis of hemorrhagic ischemic stroke. Bratisl Lek Listy 112(7):398–401PubMedGoogle Scholar
  253. 253.
    Herrmann M et al (2000) Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 31(11):2670–2677PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Olena Glushakova
    • 2
  • Stefania Mondello
    • 3
  • Ronald L. Hayes
    • 1
    Email author
  1. 1.Banyan Biomarkers, Inc.AlachuaUSA
  2. 2.Banyan Biomarkers, Inc.AlachuaUSA
  3. 3.Department of NeuroscienceUniversity of MessinaMessinaItaly

Personalised recommendations